SCHEMBL13816746

SCHEMBL13816746

C/N=C\c1ccccc1NC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.40
KDM4E B2RXH2 5/20 0.40
POLB P06746 3/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
RECQL P46063 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
USP2 O75604 1/20 0.40
HSD17B10 Q99714 1/20 0.40
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
GAA P10253 1/20 0.36
ATM Q13315 1/20 0.34
MAPK1 P28482 2/20 0.33
EGFR P00533 1/20 0.33
PABPC1 P11940 1/20 0.33
HTR6 P50406 1/20 0.33
SPHK2 Q9NRA0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22962412 0.81 MAPT (0.39) MAPTKDM4EPOLBALDH1A1HPGD
SCHEMBL20375410 0.81 MAPT (0.39) MAPTKDM4EPOLBALDH1A1HPGD
SCHEMBL14646337 0.81 MAPT (0.39) MAPTKDM4EPOLBALDH1A1HPGD
SCHEMBL24916459 0.78 IDO1 (0.38) MAPTNPSR1RAB9ASMN1; SMN2GAA
SCHEMBL19142380 0.78 MAPT (0.37) MAPTNPSR1RAB9ASMN1; SMN2GAA
SCHEMBL24023526 0.77 GAA (0.31) MAPTKDM4EALDH1A1HPGDRAB9A
SCHEMBL2495661 0.77 POLB (0.46) MAPTKDM4EPOLBALDH1A1HPGD
SCHEMBL21204295 0.76 MAPT (0.44) MAPTKDM4EPOLBALDH1A1HPGD
SCHEMBL25456261 0.74 LMNA (0.38) MAPTKDM4EALDH1A1HPGDRAB9A
SCHEMBL874034 0.73 TDP1 (0.55) MAPTKDM4EPOLBALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200231563-A1 NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 PRAGMA THERAPEUTICS (FR) 2020-07-23 US disclosed
US-10705274-B2 Optically anisotropic layer and production method therefor, optically anisotropic laminate and production method therefor, optically anisotropic transfer body, polarization plate, and image display device ZEON COPORATION (JP) 2020-07-07 US disclosed
US-20190113667-A1 OPTICALLY ANISOTROPIC LAYER AND PRODUCTION METHOD THEREFOR, OPTICALLY ANISOTROPIC LAMINATE AND PRODUCTION METHOD THEREFOR, OPTICALLY ANISOTROPIC TRANSFER BODY, POLARIZATION PLATE, AND IMAGE DISPLAY DEVICE ZEON CORPORATION (JP) 2019-04-18 US disclosed
US-8431695-B2 Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-04-30 US disclosed
EP-2067778-A1 Quinoxaline derivative, and light emitting element, licht emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200231563-A1 NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 GRM7, GRM1, GRM3 MAPT 1190/4885KDM4E 1947/4885POLB 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.